Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3
Avadel Pharmaceuticals (Nasdaq: AVDL) announced it will host a conference call and live webcast on March 3, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results, along with providing a corporate update. The webcast will be accessible through the company's investor relations website section, and a replay will be available for 90 days afterward. Interested participants are advised to register for the conference call at least 10 minutes before it begins.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha annunciato che ospiterà una conferenza telefonica e un webcast dal vivo il 3 marzo 2025, alle 8:30 ET per discutere i risultati finanziari del quarto trimestre e dell'intero anno 2024, insieme a un aggiornamento aziendale. Il webcast sarà accessibile attraverso la sezione del sito web delle relazioni con gli investitori dell'azienda, e una registrazione sarà disponibile per 90 giorni dopo. I partecipanti interessati sono invitati a registrarsi per la conferenza telefonica almeno 10 minuti prima dell'inizio.
Avadel Pharmaceuticals (Nasdaq: AVDL) anunció que llevará a cabo una conferencia telefónica y un webcast en vivo el 3 de marzo de 2025, a las 8:30 a.m. ET para discutir sus resultados financieros del cuarto trimestre y del año completo 2024, además de proporcionar una actualización corporativa. El webcast será accesible a través de la sección del sitio web de relaciones con inversionistas de la compañía, y una repetición estará disponible durante 90 días después. Se aconseja a los participantes interesados que se registren para la conferencia telefónica al menos 10 minutos antes de que comience.
아바델 제약(나스닥: AVDL)은 2025년 3월 3일 오전 8시 30분 ET에 2024년 4분기 및 전체 연도 재무 결과를 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜 및 라이브 웹캐스트를 개최할 것이라고 발표했습니다. 웹캐스트는 회사의 투자자 관계 웹사이트 섹션을 통해 접근할 수 있으며, 이후 90일 동안 재생이 가능합니다. 관심 있는 참가자는 시작 10분 전까지 컨퍼런스 콜에 등록할 것을 권장합니다.
Avadel Pharmaceuticals (Nasdaq: AVDL) a annoncé qu'elle organisera une conférence téléphonique et un webinaire en direct le 3 mars 2025 à 8h30 ET pour discuter de ses résultats financiers du quatrième trimestre et de l'année complète 2024, ainsi que pour fournir une mise à jour de l'entreprise. Le webinaire sera accessible via la section des relations avec les investisseurs du site Web de l'entreprise, et un enregistrement sera disponible pendant 90 jours après. Les participants intéressés sont invités à s'inscrire à la conférence téléphonique au moins 10 minutes avant le début.
Avadel Pharmaceuticals (Nasdaq: AVDL) gab bekannt, dass am 3. März 2025 um 8:30 Uhr ET eine Telefonkonferenz und ein Live-Webcast stattfinden werden, um die finanziellen Ergebnisse des vierten Quartals und des gesamten Jahres 2024 zu besprechen sowie ein Unternehmensupdate zu geben. Der Webcast wird über den Bereich für Investorenbeziehungen der Unternehmenswebsite zugänglich sein, und eine Wiederholung wird 90 Tage lang verfügbar sein. Interessierte Teilnehmer werden gebeten, sich mindestens 10 Minuten vor Beginn der Telefonkonferenz anzumelden.
- None.
- None.
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024.
A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionaq.com
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
When will Avadel Pharmaceuticals (AVDL) report Q4 and full year 2024 earnings?
How can investors access AVDL's Q4 2024 earnings call?
How long will AVDL's Q4 2024 earnings call replay be available?
What time should participants register for AVDL's Q4 2024 earnings call?
